These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 14600582)

  • 1. Treating advanced HIV infection.
    Boffito M; Bonora S; Sinicco A; Raiteri R; Milia MG; Khoo SH; Hoggard PG; Back DJ; Di Perri G
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):344-5. PubMed ID: 14600582
    [No Abstract]   [Full Text] [Related]  

  • 2. DMP 266 and indinavir combination.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV agents. Efavirenz versus indinavir: who really wins?
    TreatmentUpdate; 2000 Feb; 12(1):4-5. PubMed ID: 12125628
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
    Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
    Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV].
    Payan C; Brault C; Peigne M; Loison J; Chennebault JM
    Transfus Clin Biol; 2003 Apr; 10(2):72-3. PubMed ID: 12763147
    [No Abstract]   [Full Text] [Related]  

  • 6. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.
    Manfredi R; Calza L; Chiodo F
    AIDS; 2004 Nov; 18(17):2331-3. PubMed ID: 15577549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92. PubMed ID: 15373069
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment with lopinavir/ritonavir in heavily pretreated subjects failing multiple antiretroviral regimens in clinical practice.
    Romano L; Peduzzi C; Venturi G; Di Pietro M; Carli T; Corsi P; Gonnelli A; Valensin PE; Zazzi M
    J Acquir Immune Defic Syndr; 2002 Aug; 30(5):533-5. PubMed ID: 12154345
    [No Abstract]   [Full Text] [Related]  

  • 9. Initial treatment of HIV-1 infection.
    Schulz TR; Street AC
    N Engl J Med; 2008 Aug; 359(9):970; author reply 971. PubMed ID: 18753656
    [No Abstract]   [Full Text] [Related]  

  • 10. Efavirenz in HIV infection.
    Casado JL; Moreno S
    N Engl J Med; 2000 Apr; 342(17):1290-1. PubMed ID: 10787332
    [No Abstract]   [Full Text] [Related]  

  • 11. Initial treatment for HIV infection--an embarrassment of riches.
    Hirschel B; Calmy A
    N Engl J Med; 2008 May; 358(20):2170-2. PubMed ID: 18480210
    [No Abstract]   [Full Text] [Related]  

  • 12. Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Mata R; Gómez-Vera J; Alarcón A; Pachón J
    J Acquir Immune Defic Syndr; 2003 Feb; 32(2):240-2. PubMed ID: 12571537
    [No Abstract]   [Full Text] [Related]  

  • 13. [From research to clinical practice: use of lopinavir/ritonavir in monotherapy].
    Valencia-Ortega ME; Moreno-Celda V
    Enferm Infecc Microbiol Clin; 2008 Dec; 26(10):671-2. PubMed ID: 19100200
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy.
    Antoniou T; Park-Wyllie L; Boyle E
    J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1666-7. PubMed ID: 15577427
    [No Abstract]   [Full Text] [Related]  

  • 15. Choosing the best initial therapy for HIV-1 infection.
    Clumeck N
    N Engl J Med; 1999 Dec; 341(25):1925-6. PubMed ID: 10601514
    [No Abstract]   [Full Text] [Related]  

  • 16. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
    De Luca A; Cozzi-Lepri A; Antinori A; Zaccarelli M; Bongiovanni M; Di Giambenedetto S; Marconi P; Cicconi P; Resta F; Grisorio B; Ciardi M; Cauda R; Monforte Ad; ; ; ;
    Antivir Ther; 2006; 11(5):609-18. PubMed ID: 16964829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials group: two studies are now open to patients who qualify.
    Craig K
    HIV Clin; 2000; 12(1):5. PubMed ID: 11810862
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
    Fraaij PL; Neubert J; Bergshoeff AS; van Rossum AM; Hartwig NG; Schroten H; Korn K; Burger DM; de Groot R; Niehues T
    Antivir Ther; 2004 Apr; 9(2):297-9. PubMed ID: 15134193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
    Harris M; Côté H; Ochoa C; Allavena C; Negredo E; Thorne A; Cahn P; Zala C; Raffi F; Clotet B; Singer J; Montaner J;
    J Acquir Immune Defic Syndr; 2009 Mar; 50(3):335-7. PubMed ID: 19242263
    [No Abstract]   [Full Text] [Related]  

  • 20. Nucleoside-free regimen tested.
    AIDS Patient Care STDS; 2003 Jun; 17(6):309-10. PubMed ID: 12889482
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.